English
简体中文
Total: £ 56.28
Published Date: 2026-04-02 | Pages: 123 | Tables: 121 | Pharma & Healthcare
The global Menstrual Regulating Drug market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Menstrual Regulating Drug competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Menstrual regulating drugs are a class of drugs used to regulate women's menstrual cycle and related physiological symptoms, including but not limited to irregular menstruation, amenorrhea, menstrual pain, premenstrual syndrome, etc.
The North American market for Menstrual Regulating Drug is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Menstrual Regulating Drug is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Menstrual Regulating Drug include Bayer AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Johnson & Johnson, Merck & Co., Inc., AbbVie Inc., Allergan plc, Mylan N.V., GlaxoSmithKline plc, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Menstrual Regulating Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Menstrual Regulating Drug. The Menstrual Regulating Drug market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Menstrual Regulating Drug market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Menstrual Regulating Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Bayer AG
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Novartis AG
Johnson & Johnson
Merck & Co., Inc.
AbbVie Inc.
Allergan plc
Mylan N.V.
GlaxoSmithKline plc
Lupin Limited
Sun Pharmaceutical Industries Ltd.
HRA Pharma
Sandoz International GmbH
Dr. Reddy's Laboratories Ltd.
Segment by Type
Contraceptive Pills
Non-contraceptive Pills
by Application
Irregular Menstruation
Menstrual Pain
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Menstrual Regulating Drug manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Menstrual Regulating Drug sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Menstrual Regulating Drug Market Overview
1.1 Product Definition
1.2 Menstrual Regulating Drug by Type
1.2.1 Global Menstrual Regulating Drug Market Value by Type: 2025 vs 2032
1.2.2 Contraceptive Pills
1.2.3 Non-contraceptive Pills
1.3 Menstrual Regulating Drug by Application
1.3.1 Global Menstrual Regulating Drug Market Value by Application: 2025 vs 2032
1.3.2 Irregular Menstruation
1.3.3 Menstrual Pain
1.3.4 Others
1.4 Global Menstrual Regulating Drug Market Size Estimates and Forecasts
1.4.1 Global Menstrual Regulating Drug Revenue 2021–2032
1.4.2 Global Menstrual Regulating Drug Sales 2021–2032
1.4.3 Global Menstrual Regulating Drug Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Menstrual Regulating Drug Market Competition by Manufacturers
2.1 Global Menstrual Regulating Drug Sales Market Share by Manufacturers (2021–2026)
2.2 Global Menstrual Regulating Drug Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Menstrual Regulating Drug Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Menstrual Regulating Drug, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Menstrual Regulating Drug, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Menstrual Regulating Drug, Product Types and Applications
2.7 Global Key Manufacturers of Menstrual Regulating Drug, Date of Entry into the Industry
2.8 Global Menstrual Regulating Drug Market Competitive Situation and Trends
2.8.1 Global Menstrual Regulating Drug Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Menstrual Regulating Drug Players Market Share by Revenue
2.8.3 Global Menstrual Regulating Drug Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Menstrual Regulating Drug Market Scenario by Region
3.1 Global Menstrual Regulating Drug Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Menstrual Regulating Drug Sales by Region: 2021–2032
3.2.1 Global Menstrual Regulating Drug Sales by Region: 2021–2026
3.2.2 Global Menstrual Regulating Drug Sales by Region: 2027–2032
3.3 Global Menstrual Regulating Drug Revenue by Region: 2021–2032
3.3.1 Global Menstrual Regulating Drug Revenue by Region: 2021–2026
3.3.2 Global Menstrual Regulating Drug Revenue by Region: 2027–2032
3.4 North America Menstrual Regulating Drug Market Facts & Figures by Country
3.4.1 North America Menstrual Regulating Drug Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Menstrual Regulating Drug Sales by Country (2021–2032)
3.4.3 North America Menstrual Regulating Drug Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Menstrual Regulating Drug Market Facts & Figures by Country
3.5.1 Europe Menstrual Regulating Drug Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Menstrual Regulating Drug Sales by Country (2021–2032)
3.5.3 Europe Menstrual Regulating Drug Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Menstrual Regulating Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Menstrual Regulating Drug Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Menstrual Regulating Drug Sales by Region (2021–2032)
3.6.3 Asia Pacific Menstrual Regulating Drug Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Menstrual Regulating Drug Market Facts & Figures by Country
3.7.1 Latin America Menstrual Regulating Drug Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Menstrual Regulating Drug Sales by Country (2021–2032)
3.7.3 Latin America Menstrual Regulating Drug Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Menstrual Regulating Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Menstrual Regulating Drug Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Menstrual Regulating Drug Sales by Country (2021–2032)
3.8.3 Middle East and Africa Menstrual Regulating Drug Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Menstrual Regulating Drug Sales by Type (2021–2032)
4.1.1 Global Menstrual Regulating Drug Sales by Type (2021–2026)
4.1.2 Global Menstrual Regulating Drug Sales by Type (2027–2032)
4.1.3 Global Menstrual Regulating Drug Sales Market Share by Type (2021–2032)
4.2 Global Menstrual Regulating Drug Revenue by Type (2021–2032)
4.2.1 Global Menstrual Regulating Drug Revenue by Type (2021–2026)
4.2.2 Global Menstrual Regulating Drug Revenue by Type (2027–2032)
4.2.3 Global Menstrual Regulating Drug Revenue Market Share by Type (2021–2032)
4.3 Global Menstrual Regulating Drug Price by Type (2021–2032)
5 Segment by Application
5.1 Global Menstrual Regulating Drug Sales by Application (2021–2032)
5.1.1 Global Menstrual Regulating Drug Sales by Application (2021–2026)
5.1.2 Global Menstrual Regulating Drug Sales by Application (2027–2032)
5.1.3 Global Menstrual Regulating Drug Sales Market Share by Application (2021–2032)
5.2 Global Menstrual Regulating Drug Revenue by Application (2021–2032)
5.2.1 Global Menstrual Regulating Drug Revenue by Application (2021–2026)
5.2.2 Global Menstrual Regulating Drug Revenue by Application (2027–2032)
5.2.3 Global Menstrual Regulating Drug Revenue Market Share by Application (2021–2032)
5.3 Global Menstrual Regulating Drug Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Bayer AG
6.1.1 Bayer AG Company Information
6.1.2 Bayer AG Description and Business Overview
6.1.3 Bayer AG Menstrual Regulating Drug Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Bayer AG Menstrual Regulating Drug Product Portfolio
6.1.5 Bayer AG Recent Developments/Updates
6.2 Pfizer Inc.
6.2.1 Pfizer Inc. Company Information
6.2.2 Pfizer Inc. Description and Business Overview
6.2.3 Pfizer Inc. Menstrual Regulating Drug Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Pfizer Inc. Menstrual Regulating Drug Product Portfolio
6.2.5 Pfizer Inc. Recent Developments/Updates
6.3 Teva Pharmaceutical Industries Ltd.
6.3.1 Teva Pharmaceutical Industries Ltd. Company Information
6.3.2 Teva Pharmaceutical Industries Ltd. Description and Business Overview
6.3.3 Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio
6.3.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
6.4 Novartis AG
6.4.1 Novartis AG Company Information
6.4.2 Novartis AG Description and Business Overview
6.4.3 Novartis AG Menstrual Regulating Drug Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Novartis AG Menstrual Regulating Drug Product Portfolio
6.4.5 Novartis AG Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Company Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Menstrual Regulating Drug Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Johnson & Johnson Menstrual Regulating Drug Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 Merck & Co., Inc.
6.6.1 Merck & Co., Inc. Company Information
6.6.2 Merck & Co., Inc. Description and Business Overview
6.6.3 Merck & Co., Inc. Menstrual Regulating Drug Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Merck & Co., Inc. Menstrual Regulating Drug Product Portfolio
6.6.5 Merck & Co., Inc. Recent Developments/Updates
6.7 AbbVie Inc.
6.7.1 AbbVie Inc. Company Information
6.7.2 AbbVie Inc. Description and Business Overview
6.7.3 AbbVie Inc. Menstrual Regulating Drug Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 AbbVie Inc. Menstrual Regulating Drug Product Portfolio
6.7.5 AbbVie Inc. Recent Developments/Updates
6.8 Allergan plc
6.8.1 Allergan plc Company Information
6.8.2 Allergan plc Description and Business Overview
6.8.3 Allergan plc Menstrual Regulating Drug Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Allergan plc Menstrual Regulating Drug Product Portfolio
6.8.5 Allergan plc Recent Developments/Updates
6.9 Mylan N.V.
6.9.1 Mylan N.V. Company Information
6.9.2 Mylan N.V. Description and Business Overview
6.9.3 Mylan N.V. Menstrual Regulating Drug Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Mylan N.V. Menstrual Regulating Drug Product Portfolio
6.9.5 Mylan N.V. Recent Developments/Updates
6.10 GlaxoSmithKline plc
6.10.1 GlaxoSmithKline plc Company Information
6.10.2 GlaxoSmithKline plc Description and Business Overview
6.10.3 GlaxoSmithKline plc Menstrual Regulating Drug Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 GlaxoSmithKline plc Menstrual Regulating Drug Product Portfolio
6.10.5 GlaxoSmithKline plc Recent Developments/Updates
6.11 Lupin Limited
6.11.1 Lupin Limited Company Information
6.11.2 Lupin Limited Description and Business Overview
6.11.3 Lupin Limited Menstrual Regulating Drug Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Lupin Limited Menstrual Regulating Drug Product Portfolio
6.11.5 Lupin Limited Recent Developments/Updates
6.12 Sun Pharmaceutical Industries Ltd.
6.12.1 Sun Pharmaceutical Industries Ltd. Company Information
6.12.2 Sun Pharmaceutical Industries Ltd. Description and Business Overview
6.12.3 Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio
6.12.5 Sun Pharmaceutical Industries Ltd. Recent Developments/Updates
6.13 HRA Pharma
6.13.1 HRA Pharma Company Information
6.13.2 HRA Pharma Description and Business Overview
6.13.3 HRA Pharma Menstrual Regulating Drug Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 HRA Pharma Menstrual Regulating Drug Product Portfolio
6.13.5 HRA Pharma Recent Developments/Updates
6.14 Sandoz International GmbH
6.14.1 Sandoz International GmbH Company Information
6.14.2 Sandoz International GmbH Description and Business Overview
6.14.3 Sandoz International GmbH Menstrual Regulating Drug Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Sandoz International GmbH Menstrual Regulating Drug Product Portfolio
6.14.5 Sandoz International GmbH Recent Developments/Updates
6.15 Dr. Reddy's Laboratories Ltd.
6.15.1 Dr. Reddy's Laboratories Ltd. Company Information
6.15.2 Dr. Reddy's Laboratories Ltd. Description and Business Overview
6.15.3 Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Product Portfolio
6.15.5 Dr. Reddy's Laboratories Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Menstrual Regulating Drug Industry Chain Analysis
7.2 Menstrual Regulating Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Menstrual Regulating Drug Production Mode & Process Analysis
7.4 Menstrual Regulating Drug Sales and Marketing
7.4.1 Menstrual Regulating Drug Sales Channels
7.4.2 Menstrual Regulating Drug Distributors
7.5 Menstrual Regulating Drug Customer Analysis
8 Menstrual Regulating Drug Market Dynamics
8.1 Menstrual Regulating Drug Industry Trends
8.2 Menstrual Regulating Drug Market Drivers
8.3 Menstrual Regulating Drug Market Challenges
8.4 Menstrual Regulating Drug Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Menstrual Regulating Drug Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Menstrual Regulating Drug Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Menstrual Regulating Drug Market Competitive Situation by Manufacturers in 2025
Table 4. Global Menstrual Regulating Drug Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Menstrual Regulating Drug Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Menstrual Regulating Drug Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Menstrual Regulating Drug Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Menstrual Regulating Drug Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Menstrual Regulating Drug, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Menstrual Regulating Drug, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Menstrual Regulating Drug, Product Types and Applications
Table 12. Global Key Manufacturers of Menstrual Regulating Drug, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Menstrual Regulating Drug Companies by Tier (Tier 1, Tier 2, Tier 3), based on Menstrual Regulating Drug Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Menstrual Regulating Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Menstrual Regulating Drug Sales by Region (K Units), 2021–2026
Table 18. Global Menstrual Regulating Drug Sales Market Share by Region (2021–2026)
Table 19. Global Menstrual Regulating Drug Sales by Region (K Units), 2027–2032
Table 20. Global Menstrual Regulating Drug Sales Market Share by Region (2027–2032)
Table 21. Global Menstrual Regulating Drug Revenue by Region (US$ Million), 2021–2026
Table 22. Global Menstrual Regulating Drug Revenue Market Share by Region (2021–2026)
Table 23. Global Menstrual Regulating Drug Revenue by Region (US$ Million), 2027–2032
Table 24. Global Menstrual Regulating Drug Revenue Market Share by Region (2027–2032)
Table 25. North America Menstrual Regulating Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Menstrual Regulating Drug Sales by Country (K Units), 2021–2026
Table 27. North America Menstrual Regulating Drug Sales by Country (K Units), 2027–2032
Table 28. North America Menstrual Regulating Drug Revenue by Country (US$ Million), 2021–2026
Table 29. North America Menstrual Regulating Drug Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Menstrual Regulating Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Menstrual Regulating Drug Sales by Country (K Units), 2021–2026
Table 32. Europe Menstrual Regulating Drug Sales by Country (K Units), 2027–2032
Table 33. Europe Menstrual Regulating Drug Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Menstrual Regulating Drug Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Menstrual Regulating Drug Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Menstrual Regulating Drug Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Menstrual Regulating Drug Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Menstrual Regulating Drug Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Menstrual Regulating Drug Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Menstrual Regulating Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Menstrual Regulating Drug Sales by Country (K Units), 2021–2026
Table 42. Latin America Menstrual Regulating Drug Sales by Country (K Units), 2027–2032
Table 43. Latin America Menstrual Regulating Drug Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Menstrual Regulating Drug Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Menstrual Regulating Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Menstrual Regulating Drug Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Menstrual Regulating Drug Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Menstrual Regulating Drug Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Menstrual Regulating Drug Revenue by Country (US$ Million), 2027–2032
Table 50. Global Menstrual Regulating Drug Sales (K Units) by Type (2021–2026)
Table 51. Global Menstrual Regulating Drug Sales (K Units) by Type (2027–2032)
Table 52. Global Menstrual Regulating Drug Sales Market Share by Type (2021–2026)
Table 53. Global Menstrual Regulating Drug Sales Market Share by Type (2027–2032)
Table 54. Global Menstrual Regulating Drug Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Menstrual Regulating Drug Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Menstrual Regulating Drug Revenue Market Share by Type (2021–2026)
Table 57. Global Menstrual Regulating Drug Revenue Market Share by Type (2027–2032)
Table 58. Global Menstrual Regulating Drug Price (US$/Unit) by Type (2021–2026)
Table 59. Global Menstrual Regulating Drug Price (US$/Unit) by Type (2027–2032)
Table 60. Global Menstrual Regulating Drug Sales (K Units) by Application (2021–2026)
Table 61. Global Menstrual Regulating Drug Sales (K Units) by Application (2027–2032)
Table 62. Global Menstrual Regulating Drug Sales Market Share by Application (2021–2026)
Table 63. Global Menstrual Regulating Drug Sales Market Share by Application (2027–2032)
Table 64. Global Menstrual Regulating Drug Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Menstrual Regulating Drug Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Menstrual Regulating Drug Revenue Market Share by Application (2021–2026)
Table 67. Global Menstrual Regulating Drug Revenue Market Share by Application (2027–2032)
Table 68. Global Menstrual Regulating Drug Price (US$/Unit) by Application (2021–2026)
Table 69. Global Menstrual Regulating Drug Price (US$/Unit) by Application (2027–2032)
Table 70. Bayer AG Company Information
Table 71. Bayer AG Description and Business Overview
Table 72. Bayer AG Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Bayer AG Menstrual Regulating Drug Product
Table 74. Bayer AG Recent Developments/Updates
Table 75. Pfizer Inc. Company Information
Table 76. Pfizer Inc. Description and Business Overview
Table 77. Pfizer Inc. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Pfizer Inc. Menstrual Regulating Drug Product
Table 79. Pfizer Inc. Recent Developments/Updates
Table 80. Teva Pharmaceutical Industries Ltd. Company Information
Table 81. Teva Pharmaceutical Industries Ltd. Description and Business Overview
Table 82. Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product
Table 84. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 85. Novartis AG Company Information
Table 86. Novartis AG Description and Business Overview
Table 87. Novartis AG Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Novartis AG Menstrual Regulating Drug Product
Table 89. Novartis AG Recent Developments/Updates
Table 90. Johnson & Johnson Company Information
Table 91. Johnson & Johnson Description and Business Overview
Table 92. Johnson & Johnson Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Johnson & Johnson Menstrual Regulating Drug Product
Table 94. Johnson & Johnson Recent Developments/Updates
Table 95. Merck & Co., Inc. Company Information
Table 96. Merck & Co., Inc. Description and Business Overview
Table 97. Merck & Co., Inc. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Merck & Co., Inc. Menstrual Regulating Drug Product
Table 99. Merck & Co., Inc. Recent Developments/Updates
Table 100. AbbVie Inc. Company Information
Table 101. AbbVie Inc. Description and Business Overview
Table 102. AbbVie Inc. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. AbbVie Inc. Menstrual Regulating Drug Product
Table 104. AbbVie Inc. Recent Developments/Updates
Table 105. Allergan plc Company Information
Table 106. Allergan plc Description and Business Overview
Table 107. Allergan plc Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Allergan plc Menstrual Regulating Drug Product
Table 109. Allergan plc Recent Developments/Updates
Table 110. Mylan N.V. Company Information
Table 111. Mylan N.V. Description and Business Overview
Table 112. Mylan N.V. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Mylan N.V. Menstrual Regulating Drug Product
Table 114. Mylan N.V. Recent Developments/Updates
Table 115. GlaxoSmithKline plc Company Information
Table 116. GlaxoSmithKline plc Description and Business Overview
Table 117. GlaxoSmithKline plc Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. GlaxoSmithKline plc Menstrual Regulating Drug Product
Table 119. GlaxoSmithKline plc Recent Developments/Updates
Table 120. Lupin Limited Company Information
Table 121. Lupin Limited Description and Business Overview
Table 122. Lupin Limited Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Lupin Limited Menstrual Regulating Drug Product
Table 124. Lupin Limited Recent Developments/Updates
Table 125. Sun Pharmaceutical Industries Ltd. Company Information
Table 126. Sun Pharmaceutical Industries Ltd. Description and Business Overview
Table 127. Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product
Table 129. Sun Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 130. HRA Pharma Company Information
Table 131. HRA Pharma Description and Business Overview
Table 132. HRA Pharma Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. HRA Pharma Menstrual Regulating Drug Product
Table 134. HRA Pharma Recent Developments/Updates
Table 135. Sandoz International GmbH Company Information
Table 136. Sandoz International GmbH Description and Business Overview
Table 137. Sandoz International GmbH Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Sandoz International GmbH Menstrual Regulating Drug Product
Table 139. Sandoz International GmbH Recent Developments/Updates
Table 140. Dr. Reddy's Laboratories Ltd. Company Information
Table 141. Dr. Reddy's Laboratories Ltd. Description and Business Overview
Table 142. Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Product
Table 144. Dr. Reddy's Laboratories Ltd. Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Menstrual Regulating Drug Distributors List
Table 148. Menstrual Regulating Drug Customers List
Table 149. Menstrual Regulating Drug Market Trends
Table 150. Menstrual Regulating Drug Market Drivers
Table 151. Menstrual Regulating Drug Market Challenges
Table 152. Menstrual Regulating Drug Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
Table 156. Authors List of This Report
List of Figures
Figure 1. Product Picture of Menstrual Regulating Drug
Figure 2. Global Menstrual Regulating Drug Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Menstrual Regulating Drug Market Share by Type: 2025 & 2032
Figure 4. Contraceptive Pills Product Picture
Figure 5. Non-contraceptive Pills Product Picture
Figure 6. Global Menstrual Regulating Drug Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Menstrual Regulating Drug Market Share by Application: 2025 & 2032
Figure 8. Irregular Menstruation
Figure 9. Menstrual Pain
Figure 10. Others
Figure 11. Global Menstrual Regulating Drug Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Menstrual Regulating Drug Market Size (US$ Million), 2021–2032
Figure 13. Global Menstrual Regulating Drug Sales (K Units), 2021–2032
Figure 14. Global Menstrual Regulating Drug Average Price (US$/Unit), 2021–2032
Figure 15. Menstrual Regulating Drug Report Years Considered
Figure 16. Menstrual Regulating Drug Sales Share by Manufacturers in 2025
Figure 17. Global Menstrual Regulating Drug Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Menstrual Regulating Drug Players: Market Share by Revenue in Menstrual Regulating Drug in 2025
Figure 19. Menstrual Regulating Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Menstrual Regulating Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Menstrual Regulating Drug Sales Market Share by Country (2021–2032)
Figure 22. North America Menstrual Regulating Drug Revenue Market Share by Country (2021–2032)
Figure 23. United States Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Menstrual Regulating Drug Sales Market Share by Country (2021–2032)
Figure 26. Europe Menstrual Regulating Drug Revenue Market Share by Country (2021–2032)
Figure 27. Germany Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Menstrual Regulating Drug Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Menstrual Regulating Drug Revenue Market Share by Region (2021–2032)
Figure 34. China Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Menstrual Regulating Drug Sales Market Share by Country (2021–2032)
Figure 42. Latin America Menstrual Regulating Drug Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Menstrual Regulating Drug Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Menstrual Regulating Drug Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Menstrual Regulating Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Menstrual Regulating Drug by Type (2021–2032)
Figure 53. Global Revenue Market Share of Menstrual Regulating Drug by Type (2021–2032)
Figure 54. Global Menstrual Regulating Drug Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of Menstrual Regulating Drug by Application (2021–2032)
Figure 56. Global Revenue Market Share of Menstrual Regulating Drug by Application (2021–2032)
Figure 57. Global Menstrual Regulating Drug Price (US$/Unit) by Application (2021–2032)
Figure 58. Menstrual Regulating Drug Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
